Gilead Sciences (GILD) EBITDA (2008 - 2026)
Gilead Sciences (GILD) EBITDA from Jun 30, 2008 to Mar 31, 2026. The TTM Gilead Sciences (GILD) EBITDA is $11B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Gilead Sciences (GILD) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +24.78% |
| 3 Years TTM | +5.38% |
| 5 Years TTM | +17.19% |
| 10 Years TTM | -6.77% |
| All Time TTM | +9.64% |
Annual EBITDA change of Gilead Sciences (GILD)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $2.68B | -74.22% |
| 2025 | $10B | +408.66% |
| 2024 | $2.04B | -74.33% |
| 2023 | $7.96B | +4.00% |
| 2022 | $7.65B | -25.31% |
| 2021 | $10B | +135.08% |
| 2020 | $4.36B | -4.03% |
| 2019 | $4.54B | -46.10% |
| 2018 | $8.43B | -41.31% |
| 2017 | $14B | -19.39% |
| 2016 | $18B | -20.33% |
| 2015 | $22B | +45.25% |
| 2014 | $15B | +232.61% |
| 2013 | $4.63B | +13.05% |
| 2012 | $4.09B | +5.98% |
| 2011 | $3.86B | -4.16% |
| 2010 | $4.03B | +12.12% |
| 2009 | $3.59B | +31.63% |
| 2008 | $2.73B | +24.02% |
| 2007 | $2.20B | N/A |
Comparison Gilead Sciences (GILD) five years EBITDA CAGR with competitors
Gilead Sciences (GILD) five years EBITDA CAGR is 17.19%.
| Ticker | Name | five years EBITDA CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 30.95% | +80.03% |
| NVO | Novo Nordisk | 25.26% | +46.92% |
| AZN | Astrazeneca plc | 18.02% | +4.83% |
| BMY | Bristol-Myers Squibb Company | 13.61% | -20.86% |
| MRK | Merck & Co Inc | 10.17% | -40.87% |
| JNJ | Johnson & Johnson | 6.13% | -64.32% |
| NVS | Novartis AG | 5.31% | -69.09% |
| ABBV | Abbvie Inc | 4.99% | -70.96% |
| AMGN | AMGEN Inc | 4.42% | -74.30% |
| GRFS | Grifols SA | 2.72% | -84.15% |
| GSK | GSK Plc | 1.17% | -93.21% |